Pulmonary vascular disease & thromboembolism

Prevention of Venous Thromboembolism after Total Hip or Knee Replacement

N Engl J MedPublished comparative-effectiveness noninferiority trial

Authors' conclusion

Aspirin prophylaxis after total hip or knee arthroplasty was not noninferior to rivaroxaban or warfarin with respect to death or symptomatic VTE. Warfarin and rivaroxaban were not noninferior to aspirin for safety. (Funded by the Patient-Centered Outcomes Research Institute; PEPPER ClinicalTrials.gov number, NCT02810704.).

Study context

Population
Patients undergoing elective hip or knee arthroplastyrandomized, 15,317 included in the primary per-protocol analysis · 7,214 (hip arthroplasty, per-protocol) · 8,103 (knee arthroplasty, per-protocol)
Participants
18,883 patients
Comparison
Aspirin vs warfarin vs rivaroxaban for venous thromboembolism (VTE) prophylaxis
  • Aspirinn = 6,090
  • Warfarinn = 4,231
  • Rivaroxabann = 4,996
Primary endpoint
Composite primary effectiveness outcome (death from any cause or symptomatic VTE)
Follow-up
6 months
Methodological detailsrandomized, blinded outcome evaluation
  • Randomized
  • Blinded outcome evaluation

Primary result

As reported in the abstract

Composite primary effectiveness outcome (death from any cause or symptomatic VTE)
Risk difference, percentage points (95% CI)
Aspirinvs rivaroxabanpairwise risks 1.24% and 0.94%
0.30(−0.20 to 0.81)
Aspirinvs warfarinpairwise risks 1.24% and 1.01%
0.23(−0.34 to 0.81)
Warfarinvs rivaroxabanpairwise risks 1.13% and 1.10%
0.03(−0.57 to 0.63)

Safety

Primary safety outcome (bleeding, reoperation for wound problems, or myocardial infarction) · 6 months

OutcomeAspirinWarfarinRivaroxabanRisk difference (percentage points) (95% CI)
Rivaroxabanvs aspirinPairwise risks 3.70% and 3.02% · primary safety outcome · Intention-to-treat analyses yielded similar results2.91%3.36%3.48%0.68 (−0.04 to 1.41)
Warfarinvs aspirinPairwise risks 3.65% and 2.88% · primary safety outcome · Intention-to-treat analyses yielded similar results0.77 (−0.04 to 1.58)
Rivaroxabanvs warfarinPairwise risks 3.59% and 3.61% · primary safety outcome · Intention-to-treat analyses yielded similar results−0.02 (−0.89 to 0.85)

Original publication

Prevention of Venous Thromboembolism after Total Hip or Knee Replacement. N Engl J Med. Published 12 November 2026. doi:10.1056/nejmoa2602435

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.